An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Related Clinical Trial
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL. A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia Frontline Oral Arsenic Trioxide for APL A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia Total Marrow Irradiation for Refractory Acute Leukemia Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Symptom-Adapted Physical Activity Intervention in Minimizing Physical Function Decline in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS) Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission 3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PXD101 in Treating Patients With Acute Myeloid Leukemia Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Connect® MDS/AML Disease Registry Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia Vorinostat in Treating Patients With Acute Myeloid Leukemia Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly Comparison of Diagnostic Yield Among M-FISH, FISH Probe Panel and Conventional Cytogenetic Analysis in AML Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia Red Cell Transfusion Goals in Patients With Acute Leukemias A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia Fludarabine and Cytarabine as Continuous Infusion Plus G-CSF Priming for Elderly Patients With Resistant AML Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible A Safety Study of SGN-CD33A in AML Patients FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia ASCT for Relapsed APL After Molecular Remission Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup All-trans Retinoic Acid, and Arsenic +/- Idarubicin Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia AIDA 2000 Guidelines Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL French Registry of First-line Treatment of Acute Promyelocytic Leukemia New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia Proteasome Inhibition in Acute Promyelocytic Leukemia

Brief Title

An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia

Official Title

A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy

Brief Summary

      This is a Phase III, multicenter, double-blind, randomized study of pracinostat vs. placebo
      with azacitidine (AZA) as background therapy in patients ≥ 18 years of age with newly
      diagnosed acute myeloid leukemia (AML), excluding acute promyelocytic leukemia and
      cytogenetic low-risk AML, who are unfit to receive intensive remission induction chemotherapy
      due to age ≥ 75 years or comorbidities. Patients will be randomized in a 1:1 ratio to one of
      two groups: Group A (experimental group) to receive pracinostat plus AZA and Group B (control
      group) to receive placebo plus AZA. Randomization will be stratified by cytogenetic risk
      category (intermediate vs. unfavorable-risk, according to SWOG Cytogenetic Risk Category
      Definitions) and ECOG performance status (0-1 vs. 2). Treatments will be administered based
      on 28-day cycles, with pracinostat/placebo administered orally once every other day, 3 times
      a week for 3 weeks, followed by one week of no treatment and AZA administered for 7 days of
      each cycle. Study treatment should continue until there is documented disease progression,
      relapse from complete remission (CR), or non-manageable toxicity. A minimum of 6 cycles may
      be required to achieve a complete remission. Once permanently discontinued from study
      treatment, patients will enter the Long-term Follow-up phase of the study and will be
      followed for assessment of disease progression, if applicable, and survival every 3 months
      (±1 month) until death. The end of this study is defined when 390 events (deaths) have
      occurred and the study is unblinded for final overall survival analysis. Patients who are
      receiving study treatment at the end of the study may have the opportunity to continue to
      receive the study drugs to which they were randomized to (Post- Study Observation Period),
      until the Sponsor informs the Investigators of the appropriate course of action based on the
      study results. The Post-Study Observation Period is defined as the period starting from the
      end of the study for a maximum of 12 months.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Overall Survival

Secondary Outcome

 Morphologic Complete Remission (CR) Rate

Condition

Acute Myeloid Leukemia

Intervention

Pracinostat

Study Arms / Comparison Groups

 Pracinostat plus AZA
Description:  60 mg capsule orally, once a day, 3 times a week for 3 weeks, followed by 1 week of rest of each 28-day cycle. As a background therapy azacitidine (AZA) will be administered at a dose of 75 mg/m2 by SC or IV injection daily for 7 days of each 28-day cycle.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

406

Start Date

June 23, 2017

Completion Date

August 20, 2020

Primary Completion Date

August 20, 2020

Eligibility Criteria

        Inclusion Criteria:

          1. Male or female patient ≥ 18 years of age with newly diagnosed, histologically or
             cytologically confirmed, AML including de novo, secondary to antecedent hematologic
             disorders, or treatment-related disease with intermediate or unfavorable-risk
             cytogenetics

          2. Unable to receive intensive chemotherapy regimens at enrollment, based on one of the
             following:

             I. Age ≥ 75 years, or

             II. Age < 75 years with at least 1 of the following co-morbidities:

               1. An ECOG performance status of 2

               2. Clinically significant cardiovascular disease defined as:

             i. Left ventricular ejection fraction (LVEF) ≤ 50%, measured within 3 months prior to
             Day 1 confirmed by ECHO/MUGA ii. Congestive heart failure requiring medical therapy
             iii. Chronic stable angina requiring medical therapy iv. Prior cerebrovascular
             accident with sequelae c. Clinically significant pulmonary disease defined as: i.
             Forced expiratory volume in 1 second (FEV1) ≤ 65% of expected ii. Lung diffusing
             capacity for carbon monoxide (DLCO) ≤ 65% of expected Confirmed by pulmonary tests. d.
             Diabetes mellitus with symptomatic end-organ damage (e.g., retinopathy, nephropathy,
             neuropathy, vasculopathy) e. Autoimmune inflammatory conditions (e.g., rheumatoid
             arthritis, systemic lupus erythematous, inflammatory bowel disease, or similar)
             requiring chronic disease modifying therapy (e.g., etanercept, adalimumab, infliximab,
             rituximab, methotrexate, or similar) f. Class III obesity defined as a Body Mass Index
             (BMI) > 40 kg/m2 g. Renal impairment defined as serum creatinine > 1.3 mg/dL (> 115
             µmol/L) or creatinine clearance <70 ml/min h. Clinically significant cognitive
             impairment defined as requiring medical therapy and/or assistance with activities of
             daily living

          3. 20% blasts in bone marrow

          4. Peripheral white blood cell (WBC) count 30,000/µL For cyto-reduction, hydroxyurea is
             allowed during screening and up to Cycle 1, Days 1-14, to reduce WBC count to < 30,000
             µL prior to Day 1. After Cycle 1, Day 14, hydroxyurea is prohibited.

          5. ECOG performance status ≤ 2

          6. Adequate organ function as evidenced by the following laboratory findings:

               1. Total bilirubin ≤ 2 × upper limit of normal (ULN) or < 3 x ULN for patients with
                  Gilbert-Meulengracht Syndrome

               2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN

          7. Serum creatinine ≤ 1.5 × ULN according to institutional standards or creatinine
             clearance ≥ 50 mL/min

          8. QT-interval corrected according to Fridericia's formula (QTcF) ≤ 450 ms on
             electrocardiogram (ECG) at Screening

          9. Male patient who is surgically sterile, or male patient who is willing to agree to
             remain completely abstinent (refrain from heterosexual intercourse) or who use barrier
             contraceptive measures and agree to refrain from donating sperm during the entire
             study treatment period and for 3 months after the last administration of study drug

         10. Female patient who is of childbearing potential willing to use adequate contraceptive
             measures while participating on study, OR willing to completely abstain from
             heterosexual intercourse during the entire study treatment period

         11. Female patient who is of childbearing potential must have a negative serum pregnancy
             test result within 3 weeks prior to starting study drugs.

         12. Willing to provide voluntary written informed consent before performance of any study
             related procedure not part of normal medical care

         13. Willing and able to understand the nature of this study and to comply with the study
             and follow-up procedures.

        Exclusion Criteria:

          1. Able to receive intensive induction chemotherapy

          2. AML-associated inv(16)/t(16;16)/del(16q), t(15;17) (i.e. promyelocytic leukemia)
             with/without secondary aberrations; t(8;21) lacking del (9q) or complex karyotypes

          3. Presence of an active malignant disease within the last 12 months, with the exception
             of adequately treated cervical cancer in-situ, non-melanoma skin cancer and
             superficial bladder tumors (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1
             [tumor invades lamina propria]). Other malignancies may be considered after
             consultation with the Medical Monitor

          4. Life-threatening illnesses other than AML, uncontrolled medical conditions or organ
             system dysfunction that, in the Investigator's opinion, could compromise the patient's
             safety or put the study outcomes at risk

          5. Uncontrolled arrhythmias; any Class 3-4 cardiac diseases as defined by the New York
             Heart Association (NYHA) functional classification

          6. Evidence of AML central nervous system (CNS) involvement

          7. Previous chemotherapy for AML except for the following, which are allowed:

               1. Hydroxyurea for cytoreduction

               2. One course of hypomethylating agent therapy (i.e.; up to 7 doses of azacitidine
                  or 3-5 days of decitabine) within 30 days prior to enrollment (Day 1)

          8. Use of experimental drugs ≤ 30 days prior to screening

          9. Received prior HDAC inhibitor therapy

         10. Received prior treatment with a hypomethylating agent, except as allowed in Exclusion
             Criterion 7.b

         11. Known hypersensitivity to any components of pracinostat, azacitidine, or mannitol

         12. History of human immunodeficiency virus (HIV) or an active and uncontrolled infection
             with hepatitis C virus (HCV) or hepatitis B virus (HBV)

         13. Gastrointestinal (GI) tract disease that causes an inability to take oral medication,
             malabsorption syndrome, or a requirement for IV alimentation; prior surgical
             procedures affecting absorption; or uncontrolled inflammatory GI disease (e.g.,
             Crohn's disease, ulcerative colitis)

         14. Any disease(s), psychiatric condition, metabolic dysfunction, or findings from a
             physical examination or clinical laboratory test result that would cause reasonable
             suspicion of a disease or condition, that contraindicates the use of pracinostat
             and/or AZA, that may increase the risk associated with study participation, that may
             affect the interpretation of the results, or that would make the patient inappropriate
             for this study

         15. Breast-feeding woman

         16. current smokers(use of patches, chewing gums and vaping nicotine conaining fluids is
             permitted). Patients who stopped smoking at least 8 day prior to first pracinostat
             dosing can be enrolled, provided they refrain from smoking during the whole study

         17. prohibited concomitant medications

         18. uncontrolled infections

         19. receive more than 1 prior cycle of HMA or bone marrow transplant for any prior
             hematological disorder antecedent to AML
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Guillermo Garcia-Manero, MD, , 

Location Countries

Argentina

Location Countries

Argentina

Administrative Informations


NCT ID

NCT03151408

Organization ID

PRAN-16-52


Responsible Party

Sponsor

Study Sponsor

Helsinn Healthcare SA

Collaborators

 Clinipace Worldwide

Study Sponsor

Guillermo Garcia-Manero, MD, Study Chair, MD Anderson


Verification Date

February 2022